... of NSCLC in terms of etiopathogenesis and tumor biology. Since the introduction of the reversible EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib, patients with metastatic EGFR mutation-positive lung cancer can be offered a therapeutic alternative that has proven its superiority over...

...Naoki Takashima; Tomoki Kimura; Naohiro Watanabe; Takumi Umemura; Shinya Katsuno; Keiko Arakawa; Masahiro Fukatsu; Naoto Nakamura; Osamu Nishiyama; Kensuke Kataoka; Yasuhiro Kondoh; Hiroyuki Taniguchi Background: Severe skin rash as toxicity of erlotinib has been reported in relation to better...

...Cem Onal; Huseyin Abali; Zafer Koc; Sibel Kara Background: Radiation recall pneumonitis (RRP) occurs in a previously irradiated field and is triggered by certain cytotoxic drugs, principally chemotherapeutic agents such as erlotinib. Erlotinib is a reversible epidermal growth factor receptor...

... and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK...

...Haruhiro Saito; Shuji Murakami; Tetsuro Kondo; Fumihiro Oshita; Kazumasa Noda; Kouzo Yamada Background: There have been reports on the use of erlotinib in non-small cell lung cancer (NSCLC) patients after gefitinib resistance occurs, and it has been stated that erlotinib may be beneficial...

... Erlotinib Inflammation Lung cancer Letter to the Editors · Brief an die Herausgeber Onkologie 2011;34:559 560 DOI: 10.1159/000332123 Published online: September 16, 2011 Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Meningitis Erlotinib EGFR-TKI Hiroaki Satoh, MD Letter to the Editors · Brief an die Herausgeber Onkologie 2011;34...

... · Side effects, cutaneous · Epidermal growth factor receptor · Tyrosine kinase inhibitor · Erlotinib Summary The epidermal growth factor receptor (EGFR) is expressed in a variety of human tissues and is a key mediator of numerous cellular processes. Dysregulation and over­ expression of the EGFR...

..., Universitätsklinikum Düsseldorf, e Institut für Pathologie, Ruhr-Universität Bochum, Deutschland Schlüsselwörter Pankreaskarzinom · R-Klassifikation · Radiochemotherapie · Adjuvante Therapie · Gemcitabin · Erlotinib · «High-Volume»-Pankreaszentren Key Words Pancreatic cancer · R classification · Radiochemotherapy...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. EGFR Mutation Gefitinib Erlotinib Lung cancer Original Article · Originalarbeit Onkologie 2010;33:231 238 DOI: 10.1159/000302729 Published...

... Erlotinib Positronen-Emissions-Tomographie Bestrahlungsplanung © 2009 S. Karger AG, Basel 2009 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic...

... Strahlentherapie Chemotherapie Gezielte Therapie Erlotinib Onkologie 2008;31(suppl 3):15 22 DOI: 10.1159/000127751 Therapie des älteren Patienten* Hendrik C. Dienemanna Wilfried Eberhardtb Rainer Fietkauc, d Martin Recke a Thoraxklinik am Universitätsklinikum Heidelberg, b Innere Klinik Tumorforschung...

... radiotherapy and systemic therapy. Tyrosine kinase inhibitors like erlotinib with its proven activity in non-small cell lung cancer may provide clinical benefits in such patients. Patients and Methods: Two case reports are presented illustrating the efficacy of erlotinib in patients with recurrent brain...